Oncology

he median progression-free survival was 11.14 months with ivonescimab and 5.85 months with pembrolizumab (Hazard Ratio [HR], 0.51; 95% CI, 0.38-0.69; P NSCLC, and patients with brain metastases.  Read More ›

Despite ranking among the top 6 wealthiest economies in the world per capita, the United States still has sizable health disparities among its citizens, which are rooted in social, economic, and environmental factors. A comprehensive local approach was developed at Carolina Blood and Cancer Care Associates to include support from all segments of the health ecosystem. Read More ›

This new feature aims to provide ongoing lists of US-based phase 2 or 3 clinical trials that are actively recruiting, and it can be used to encourage patients to enroll in a clinical trial. This issues feature is focused on sarcoma. Read More ›

Shield, Guardant Health has been FDA approved and is now covered by Medicare as the first blood test for primary colorectal cancer (CRC) screening. Read More ›

On June 26, 2024, the FDA approved epcoritamab-bysp (Epkinly; Abbvie and Genmab) as the first and only T-cell engaging bispecific antibody administered subcutaneously for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after ≥2 lines of prior therapy. Read More ›